PMID: 9648870Jul 2, 1998Paper

Distinct differences between morphine- and [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin-mu-opioid receptor complexes demonstrated by cyclic AMP-dependent protein kinase phosphorylation

Journal of Neurochemistry
S ChakrabartiH H Loh

Abstract

The present study demonstrates a conditional, agonist-dependent phosphorylation of the mu-opioid receptor (MOR-1) by cyclic AMP-dependent protein kinase (PKA) in membrane preparations of MOR-1-transfected neuroblastoma Neuro2A cells. Opioid agonist-dependent phosphorylation occurs in a time- and concentration-dependent manner (EC50 approximately 40 nM) and can be abolished by the receptor antagonist naloxone. Stoichiometric analysis indicates incorporation of a maximum of 6 mol of phosphate/mol of receptor in the presence of 1 microM morphine and 6 nM PKA. Although morphine and related alkaloids as well as some peptide agonists (PLO17 and beta-endorphin) stimulated phosphorylation of MOR-1 by PKA, the potent mu-opioid-selective peptide [D-Ala2,N-MePhe4,Gly-ol5]-enkephalin (DAMGO) or other enkephalin analogues such as [D-Ala2]-Met5-enkephalinamide (DALA), [D-Ala2,D-Leu5]-enkephalin (DADLE), and Met5-enkephalin had no effect. The lack of the effect of DAMGO on MOR-1 phosphorylation state was evident also after chronic pretreatment. These results suggest the existence of different agonist-dependent conformations of MOR-1. Furthermore, phosphorylation may be a useful parameter with which to identify different agonist-receptor confo...Continue Reading

Citations

Oct 20, 1999·Journal of Peptide Science : an Official Publication of the European Peptide Society·G SavianoT Tancredi
Jun 3, 2000·Annual Review of Pharmacology and Toxicology·P Y LawH H Loh
Aug 5, 2011·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·María Rodríguez-MuñozJavier Garzón
Jan 12, 2001·Physiological Reviews·J T WilliamsO Manzoni
Jan 1, 2003·World Journal of Gastroenterology : WJG·Xin-Hua LiuGang Li
Jul 18, 2002·Nature Reviews. Drug Discovery·Terry Kenakin
Dec 1, 2006·Expert Opinion on Drug Discovery·Terry Kenakin
Feb 7, 2019·Molecular Pharmacology·Nathaniel A Jeske
Jan 25, 2002·Annual Review of Pharmacology and Toxicology·Terry Kenakin
May 31, 2003·Nature Reviews. Drug Discovery·Terry Kenakin
Oct 27, 2004·British Journal of Pharmacology·Mark ConnorMacDonald J Christie
Aug 17, 2002·The Journal of Pharmacology and Experimental Therapeutics·Jing-Gen Liu, Paul L Prather
Nov 18, 2000·British Journal of Pharmacology·C HarrisonD G Lambert
Aug 6, 2005·The Journal of Biological Chemistry·Denise M KenskiKevan M Shokat
Jun 5, 1999·European Journal of Pharmacology·S AlloucheP Jauzac
Dec 13, 2000·Brain Research. Molecular Brain Research·A BarralloR E Rodríguez
Jul 23, 2003·Trends in Pharmacological Sciences·Terry Kenakin
Jul 13, 2006·Life Sciences·Zaijie Jim Wang, Lili X Wang
Jul 18, 2006·Neuroscience Letters·Franscisco Alvar AlvarezRaquel E Rodríguez
Jun 6, 2006·Cellular Signalling·Nicolas MarieStéphane Allouche

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antibody Specificity

Antibodies produced by B cells are highly specific for antigen as a result of random gene recombination and somatic hypermutation and affinity maturation. As the main effector of the humoral immune system, antibodies can neutralize foreign cells. Find the latest research on antibody specificity here.